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Abstract: Spirometry is difﬁ  cult for some COPD patient to perform. Volumetric capnography 
could be a second choice test to evaluate the severity of functional disturbances. The aim of this 
work is to test this hypothesis. A total number of 98 subjects were classiﬁ  ed either as normal 
ex-smokers (N = 14) or COPD patients. The latter were staged following GOLD recommen-
dations. Spirometry and volumetric capnography recordings were obtained from each patient. 
Spirometry parameters, Bohr Dead Space (VD
Bohr), Airways Dead Space from the pre-interface 
expirate corrected curve (VD
aw), Phase III slope (SlIII) and Volume of alveolar ejection (VAE) 
were measured. Index of Ventilatory Efﬁ  ciency (IVE), and Index of Airways Heterogeneity 
(IAH) were calculated as: IVE = VAE/(VT – VD
aw) and IAH = 1 – [(VT – VD
Bohr)/(VT – VD
aw)]. In 
ANOCOVA analysis IAH showed the greatest association with stage (F > 40), with no signiﬁ  -
cant covariant dependence on VT. A receiver operating characteristics curve analysis showed 
values of the area under the curve greater than 0.9 for IAH and IVE at all stage levels, with a 
sensitivity = speciﬁ  city value greater than 80%. We conclude that IAH and IVE can be used 
when spirometry cannot be reliably performed, as an alternative test to evaluate the degree of 
functional involvement in COPD patients.
Keywords: capnography, chronic obstructive pulmonary disease, dead space, pulmonary 
heterogeneity, receiver operating characteristics curve, spirometry
Introduction
Stable chronic obstructive pulmonary disease (COPD) can be evaluated by means 
of standard spirometry in a large majority of patients. In fact, spirometry is the gold 
standard to diagnose and classify COPD patients, and the severity of the disease. When 
properly performed, spirometry is the most reproducible, standardized and objective 
way of measuring ﬂ  ow limitation. A correct spirometry manoeuvre, however, requires 
the ability to clearly understand the manoeuvre, the intellectual capacity to perform it, 
and the absence of clinical limitations which might prevent several maximal forced 
expiratory manoeuvres from being performed. It is relatively common to deal with 
subjects with disabled intellectual capacity, with language difﬁ  culties, or clinical situ-
ations that make the forced expiratory manoeuvres painful or may even preclude them 
(chest pain, coronary vascular disease, minimal efforts dyspnoea, etc) In such cases 
spirometry is a poor cost/beneﬁ  t procedure. Other situations such as intubation or tra-
cheotomy, or patients lying in bed also limit the application of standard spirometry.
Pulmonary heterogeneity is, together with airways obstruction, a cardinal feature 
in the functional impairment of COPD. Heterogeneity, mostly dependent of peripheral 
involvement, is seen to increase with the severity of the disease; therefore, volumetric 
capnography, a technique that basically explores regional distribution, can be expected 
to correlate with the severity of disease in COPD patients. Previous authors have out-
lined the good relationship between changes in volumetric capnography parameters 
and the severity of COPD (Kars et al 1995; Kars et al 1997; Wilschut et al 1999; International Journal of COPD 2007:2(3) 382
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and Koulouris et al 2001); however, the diagnostic value 
of volumetric capnography has not been systematically 
explored. Recent studies reduce the intrinsic variability of 
the parameters, either by using internal relationships (Romero 
2001), a procedure that reduces the noise-to-signal ratio, or 
by using the reference values reported by Åström et al (2000) 
in normal people.
Volumetric capnography parameters are measured in 
continuous scales. Their use as a diagnostic test requires the 
selection of a cut-off value in the original scale in order to 
deﬁ  ne positive and negative test outcome. Comparison of 
the dichotomised test results with the clinical status of the 
patient, evaluated as the disease stage from Global Initiative 
for Chronic Lung Disease (GOLD) classiﬁ  cation (a spirom-
etry based criterion) (GOLD 2006), allows estimation of the 
test’s diagnostic sensitivity (Se) and speciﬁ  city (Sp), and 
determines the cut-off values that concurrently optimise Se 
and Sp. According to the hypothesis that volumetric capnog-
raphy could be an alternative test to determine the amount of 
functional involvement in COPD patients, we have designed 
a study to compare the diagnostic value of volumetric cap-
nography with spirometry as gold standard.
Methods
Subjects
A group of 84 patients (18 women, 66 men; age 60 ± 13 years, 
mean ± standard deviation) with clinical symptoms of COPD 
have been selected from patients attending the Pulmonary 
Function Laboratory. This protocol was approved by the 
Hospital’s Research Committee. Patients were asked to give 
their consent for statistical use of the results of functional 
studies. The selection criteria were: clinical diagnosis of 
COPD based on clinical symptoms and history of exposure to 
cigarette smoking. Age limits were 30 to 80 years, and body 
mass index (BMI) was limited to 35. Exclusion criteria were 
cardiovascular comorbidity disease, sequelae of tuberculosis 
on the chest X-ray or any other coexistent lung disease, and 
neuromuscular or other diseases causing loss of ventilatory 
capacity. In order to exclude asthmatics, patients with a 
change of more than 12% in FEV1 after bronchodilator were 
excluded. Subjects were classiﬁ  ed according to the Global 
Initiative for Chronic Lung Disease (GOLD) criteria (GOLD 
2006) into ﬁ  ve groups:
–  Group 0 (N = 33) or subjects at risk, with normal spi-
rometry (FEV%FEC 70%, FEV1%pred 80%), but 
symptoms (cough, sputum).
–  Group I (N = 1) or mild COPD, with FEV1%FVC 70%, 
but FEV1%pred 80%.
–  Group II (N = 20) or moderate COPD, with FEV1%FVC < 
70%, and 50% FEV1%pred 80%.
–  Group III (N = 19) or moderate to severe COPD, with 
FEV1%FVC 70%, and 30% FEV1%pred 50%.
–  Group IV (N = 18) or severe COPD, with FEV1%FVC 
70%, and FEV1%pred 30%.
In these ﬁ  ve groups FEV1 and FVC post-bronchodilator in 
percent of predicted were considered. A group of 14 normal 
subjects (6 women, 8 men; age 48 ± 11 years, mean ± SD), 
ex-smokers (more than 10 years of cessation) but free of 
symptoms was also studied, and is called “Ex-Smok” Group. 
The same exclusion criteria were applied. Table 1 shows the 
descriptive and spirometric data for the different groups. All 
COPD subjects were in a stable situation, with no changes 
in respiratory symptoms during the month prior to the study, 
and no acute episodes of respiratory failure more than six 
months. Patients were asked not to have any inhaled therapy 
in the previous twelve hours. They sat down for at least half 
an hour before the procedure.
Instrumentation
The equipment used was a Cosmo Plus System (Novametrix 
Medical Systems Inc, Wallinford, CT, USA), which measures 
CO2 concentration by means of a mainstream infrared cell, 
and airﬂ  ow by an integrated pitot type pneumotachograph. 
Optical CO2 calibration and zero ﬂ  ow were performed before 
each measurement. The instrumental dead space (mouth-
piece plus pneumotachograph and infrared cell chamber) 
was 18 ml. Pneumotachograph linearity was conﬁ  rmed 
in the experimental range of ﬂ  ows, with increasing static 
ﬂ  ows measured by means of a rotameter (Collins, Braintree, 
Table 1 Descriptive statistical data of the different groups of 
subjects studied
Group N  Sex  Age BMI FEV1 FVC  MEF50
   ♀/♂ yrs    %pr  %pr  %pr
Ex-Smok  14  6/8  48  24.2 100.3  93.2 109.3
      ± 11.1   ± 2.04   ± 8.9   ± 7.78   ± 14.7
GOLD  0  26  13/13  52  27.1 86.3 84.2 67.8
      ± 14.8   ± 4.37   ± 16.2   ± 17.3   ± 18.0
GOLD  I  1  0/1  57 32 88.6  98.5  42.9
GOLD  II  20  2/18  63  26.5 58.4 73.5 26.1
      ± 11.4   ± 4.16   ± 7.32   ± 13.0   ± 8.2
GOLD  III  19  3/16  64  25.5 40.1 59.2 16.2
      ± 13.1   ± 4.5   ± 5.73   ± 10.1   ± 7.8
GOLD  IV  18  0/18  62  25.8 22.4 42.4 7.42
      ± 9.5   ± 4.49   ± 5.2   ± 14.9   ± 2.72
Abbreviations: BMI body mass index; FEV1%pr, forced expiratory volume at the 
ﬁ  rst second in percent of predicted; FVC%pr, forced vital capacity in percent of 
predicted; MEF50%pr, maximal expiratory ﬂ  ow at 50% FVC in percent of predicted. 
Note: Mean ± Standard Deviation. International Journal of COPD 2007:2(3) 383
Capnography and COPD staging
Mass, USA). Expiratory ﬂ  ow and volume are expressed in 
BTPS conditions. Response characteristics of mainstream 
capnograph, as well as the validity of optical calibration, 
was determined by ﬂ  owing a gas mixture containing 5% (in) 
or 0% (out) CO2 in air by means of a syringe at step chang-
ing ﬂ  ow rates in the range of the physiological rates. Delay 
between ﬂ  ow and capnographic signal and capnograph time 
constant were determined by analyzing the system’s step 
response between 5% and 0% CO2 in air. In all cases delay 
was measured as the time elapsed between the beginning of 
ﬂ  ow transition according to the pneumotachographic record-
ing, and the breakpoint of the capnographic recording. Aver-
age delay was 58.9 ± 16.2 ms. Time constant was determined 
as the time to reach 63.2% of the total step response, and 
was 24.4 ± 2.35 ms. Capnographic signal was time shifted 
according to the time delay.
Measurements: Capnographic recording was always 
performed before spirometry. Subjects were sitting during 
the recording procedure, breathing through a mouthpiece 
and with a nose clip. After two to three minutes of stable 
breath, CO2 and ﬂ  ow signals were continuously recorded for 
two more minutes, digitalised at sampling frequency of 100 
Hz and stored in magnetic media. Forced spirometry was 
performed with patient in standing position by means of a 
Fleisch pneumotachograph (GS-System, Collins, Braintree, 
MA, USA) according to ATS/ERS Standardization of 
Spirometry (ATS/ERS, http://www.thoracic.org/sections/
publications/statements/pages/pfet/pft2.html, update 2006). 
Spirometry was processed by GS software, and results 
expressed in BTPS conditions. To accept spirometry results, 
at least three manoeuvres with a reproducibility of 5% and a 
difference between the best and second best FEV1 and FVC 
below 150 ml had to be recorded. A maximum of eight forced 
expiratory manoeuvres were performed. Maximal values of 
forced expiratory ﬂ  ow in one second (FEV1), Forced Vital 
Capacity (FVC) and Maximal Mid Expiratory Flow between 
25 and 75% of FVC (MMEF) were retained. The minimum 
time between manoeuvres was three minutes (of longer if 
requested by the patient). Spirometric manoeuvres were 
repeated 15 minutes after inhalation of 400 μg of salbuta-
mol by means of a spacing chamber. According to recorded 
observations, time consumption by spirometric tests oscil-
lated between about 20 minutes (the fastest) and 50 minutes 
(the slowest) plus the time consumed by the reversibility 
test. Predicted spirometric values were calculated from age, 
height and sex according to Roca et al (1986).
Volumetric capnography parameters: A recording con-
taining a minimum of ﬁ  fteen complete breathing cycles, 
at a minimal tidal volume of 150 ml was processed for 
every patient. Every cycle was identiﬁ  ed from the pneumo-
tachographic signal, isolated and analysed separately by a 
computer procedure. Cycles not accepted for measurements 
were those with a PETCO2 5 mmHg lower or higher than the 
average PETCO2 . Also discarded were cycles with a tidal 
volume above or below 25% of average VT. Final results give 
the average of the measurements done on seven to ﬁ  fteen 
cycles for each patient.
End tidal CO2 fractional concentration (FETCO2): to 
avoid the artefact of cardiac oscillations, FETCO2 was mea-
sured on the CO2 elimination (VCO2) versus expired volume 
(V) curve [VCO2 = ∫FECO2·dV], as the linear slope between 
expired volume and VCO2 of the segment deﬁ  ned by the end 
expiratory 10% of the total number of expiratory samples 
of each breath (Figure 1). End-tidal partial pressure of CO2 
(PETCO2) was calculated from barometric pressure (PB) as: 
FETCO2·(PB – PH2O).
Bohr Dead Space (VD
Bohr) was calculated according to 
classical principles, assuming that end-tidal fraction of CO2 
represents alveolar fractional concentration in the equation:
  V/ V = 1 ( V C O / V ) / F C O D
Bohr
TE 2 T E T 2 −
 
[1]
where VECO2 is the CO2 eliminated by breath.
Pre-interface expirate (PIE) was calculated according 
to Wolff and Brunner’s method (Wolff and Brunner 1984). 
In short, the volume expired when CO2 has reached half of 
the end-expiratory value is doubled, the rest of the points are 
excluded from further analysis. Then the ﬁ  rst derivative of 
the signal (dFECO2/dV) is plotted against the volume, and the 
mean of this normalized distribution function is calculated. 
The volume at which this mean value is obtained represents 
the minimal mean volume of the convective airways, also 
called the pre-interface expirate or PIE (Wolff and Brunner 
1984). Physiologically speaking, PIE represents the expired 
volume at which the interface between airways and alveolar 
gas is appreciated at airways opening.
Phase III slope (SlIII ): the curve between PIE and VT is 
divided into four segments. According to Åström et al (2000), 
SlIII was calculated as the slope of the linear regression 
between FECO2 and Volume for the two central segments.
Series dead space (VD
ser): The curve was corrected for 
the SlIII between PIE and end tidal volume. From the corrected 
new curve, serial dead space volume (VD
ser) was calculated 
by the equal area method. This procedure prevents over-
correction of phase II (Åström et al 2000). Airways dead International Journal of COPD 2007:2(3) 384
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Figure 1 Top: Expired volume and VCO2 sampled curves. Bottom: Measurements of end expiratory CO2 concentration. For detail please see the text.International Journal of COPD 2007:2(3) 385
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space (VD
aw) was obtained by subtracting Instrumental Dead 
Space (18 ml) from VD
ser.
Index of Alveolar Inhomogeneity (IAH): According to 
previous studies (Kars et al 1995; Romero 2001) the differ-
ence between VD
ser and VD
Bohr is mainly due to impairment of 
regional distribution, which distorts the curve beyond PIE. 
An index of heterogeneity was calculated by relating both 
magnitudes according to:
  IAH
VV
VV
TD
Bohr
TD
ser (%) =−
− ()
− ()
⎡
⎣
⎢
⎢
⎤
⎦
⎥
⎥
× 1 100 [2]
Index of Ventilatory Efﬁ  ciency (IVE): Alveolar exhaled 
volume or VAE was determined from the VCO2 versus expired 
volume or VCO2(V) curve, according to previous studies 
(Romero et al 1997; Blanch et al 1999). In short, after the 
linear ﬁ  tting of the last end-expiratory segment previously 
described, the slope of this curve was decreased by 6% by 
pivoting on the end expiratory point. The new straight line 
crosses the VCO2(V) curve at a single point. The volume 
between this and the end-expiratory point corresponds to 
VAE (Figure 2). This volume tends to decrease as serial 
contamination of alveolar gas, heterogeneity, and phase II 
increase. As VAE directly depends on VT and VD
ser, it seemed 
appropriate to express it in relation to these magnitudes. An 
index of ventilatory efﬁ  ciency (IVE) has been calculated as 
follows:
  IVE
V
VV
AE
TD
ser (%) =
−
×100  [3]
We used a 6% change in end tidal slope of VCO2(V) curve 
rather than the 5% used in previous studies in ventilated 
patients, because we have observed less variability in spon-
taneously breathing patients when using 6% (CVar% ± SD: 
9.14 ± 3.34, and 10.98 ± 4.16 at 6% and 5% respectively. 
N = 16 patients, twenty consecutive cycles each).
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Figure 2 Measurement of the volume of alveolar ejection (VAE) from the VCO2 versus expired volume curve. For detailed instructions, please see the text.International Journal of COPD 2007:2(3) 386
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Statistical analysis: tests of normality (Kolmogorof-
Smirnof) and homogeneity of variances (Levene homocedas-
ticity test) were applied to data prior to deciding which test 
to use to compare the groups identiﬁ  ed according to GOLD 
classiﬁ  cation. For variables normally distributed, and with 
homogeneous variances, ANOVA analysis was performed. 
Tidal volume was added as covariant when necessary. If 
normality and homocedasticity tests failed at an error of 
5%, the Kruskal-Walis rank test was applied to evaluate the 
differences between groups.
A multivariate model including Height, Body Mass Index, 
age, FEV1%pred, Tidal volume and MMEF%pred was used 
to determine the association of capnography parameters 
with functional data, and the possible confounding effect 
of factors relatively independent of respiratory functional 
abnormalities.
Receiver operating characteristic (ROC) curve analysis 
was performed to test the ability of each volumetric capnog-
raphy parameter to detect the different levels of disease char-
acterised by the GOLD Stages. The analysis was performed 
by cutting-off the population at increasing GOLD Stages 
of the disease. For each Stage Level, each parameter, con-
sidered as one-class classiﬁ  er, was progressively increased 
or decreased in step values (threshold changes). Sensitivity 
(Se) and speciﬁ  city (Sp) were calculated for each threshold 
change and expressed as a percentage. For each parameter 
at every stage ROC curves were constructed by plotting 
sensitivity against the false positive rate (100-speciﬁ  city). 
The area under the curve (AUC) and conﬁ  dence intervals 
at 95% were calculated to determine the degree and limits 
of accuracy of the curves, allowing paired comparisons. To 
determine cut-off points for each parameter at every stage, 
we calculated the point at which sensitivity equals speciﬁ  city 
(Se = Sp). Positive and Negative Predicted Values were 
calculated using Bayes theorem (Greiner and Gardner 2000) 
based on COPD prevalence observed by Kornmann et al 
(2003) at stages levels II, III and IV, and internal prevalence 
at stage 0. MedCalc® and SPSS® statistical packages were 
used for statistical analysis.
Results
Table 2 shows the descriptive statistics (mean, standard 
deviation) of capnography parameters in the COPD groups, 
as well as statistical data from ANOVA test. Variables 
ΔSlIII and IVE did not meet the criteria of homocedastic-
ity, and the Kruskal-Wallis test was applied. Group I was 
excluded, because it had only one subject. Although no 
signiﬁ  cant between groups difference was observed for 
VT, this parameter was used as covariant in the ANOVA 
analysis because of the documented tidal dependence of 
capnography variables (Åström et al 2000; Kornmann 
et al 2003), and the high dispersion of VT. In Table II values 
of F (or χ2) and P are given for between groups difference 
(F(χ2)group, and Pgroup) and VT covariant effect (Fcov, and Pcov). 
VD
aw showed no signiﬁ  cant between-groups difference, but 
did show high dependence on VT. PETCO2 showed mainly 
group, but also some VT dependence. VD
Bohr/VT showed both 
group and tidal volume dependence. When corrected for 
predicted value, however, (Δ = real-predicted, ΔVD
Bohr/VT) 
the covariant effect disappeared, but the group effect was 
maintained. Finally, IAH showed strong group but no VT 
dependence.
Table 3 shows the results of the multivariate linear 
regression. Signiﬁ  cance P gives the probability associ-
ated to the rejection of the null hypothesis stating that 
the regression coefﬁ  cient (Coeff) for a given independent 
variable is different from zero, at an alpha error below 5%. 
Variables in the equation (P < 0.05) are marked in bold. 
The Beta statistic or regression coefﬁ  cient for typiﬁ  ed 
variables, allows a non dimensional comparison of the 
degree of association between dependent and independent 
variables. The narrowest association between FEV1%pred 
and capnography parameters was observed for IAH. This 
association was not confounded by other associations 
with the independent variables considered. In contrast, 
ΔVD
Bohr/VT showed some extra dependence on age, but 
its association with FEV1%pred was still high. ΔSlIII also 
showed a good correlation with FEV1%pred, but was 
greatly confounded by a high dependence on VT. Finally 
IVE was well deﬁ  ned by a model including FEV1%pred, 
MMEF%pred, and age.
Using capnography parameters as independent variables, 
FEV1% pred was well deﬁ  ned (R = 0.836) by a multivariate 
linear model including IAH and ΔVD
Bohr/VT (beta = –0.976, 
and 0.200 respectively) with the equation:
FEV pred IAH 1(% ) . .
.( / )
=− ×
+×
112 08 5 60
11 0 Δ VD
Bohr VT  
Figure 3 shows the ROC curves constructed for 0, II, III 
and IV threshold stages of the disease at increasing values 
of IAH, SlIII, and ΔVD
Bohr/VT, or decreasing values of IVE. 
Table 4 shows the numerical analysis of the ROC curves, 
including AUC with 95% conﬁ  dence intervals, the cut-off 
value at which sensitivity equals speciﬁ  city, the value of 
sensitivity (or speciﬁ  city) at this cut-off, positive predicted International Journal of COPD 2007:2(3) 387
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value (PPV), and negative predicted value (NPV) calculated 
either from internal prevalence at stage level 0, or from the 
cumulative prevalence calculated from Kornmann et al 
(2003) for the remaining stage levels. A visual inspection 
of the ROC curves in Figure 3 shows that IAH and IVE 
seem more accurate than SlIII, and ΔVD
Bohr/VT to stage COPD 
patients. More precise information about the accuracy of 
capnography indices is obtained from numerical analysis 
of ROC curves. AUC, taken as a global summary statistic 
of diagnostic accuracy, shows higher values for IAH and 
IVE than SlIII, and ΔVD
Bohr/VT, especially for diagnosis at 
low stage levels of the disease. Paired comparison between 
AUC showed the following differences with IAH: SlIII, and 
ΔVD
Bohr/VT at stages 0 and II; ΔVD
Bohr/VT and IVE at stage 
III; and ΔVD
Bohr/VT at stage IV. Sensitivity (and speciﬁ  city) 
was similar and higher than 80% at all threshold levels for 
IAH, and IVE. In all cases PPV decreased with the threshold 
level of the disease, and the opposite was observed for NPV. 
The positive likelihood ratio (PLR) (ratio between the prob-
ability of observing the test result in diseased individuals, and 
Table 2 Comparison of groups by ANOVA or Kruskal-Wallis test. VT is used as covariant in ANOVA test. Values of χ2 are marked 
with an asterisk
Group N  STAT  VT V D
aw P ETCO2 IAH  IVE  VD
Bohr/VT  Δ(VD
Bohr/VT)  ΔSlIII
      ml  ml  mmHg  % % %  %  mmHg/L
Ex-smok 14  mean  548  115  38.2 4.62 84.8 32.0  7.48  12.78
    ± SD   ± 209   ± 34   ± 3.76   ± 1.46   ± 8.16   ± 6.27   ± 4.25   ± 7.14
GOLD  0 26  mean  530  99  34.2 7.54 70.0 31.6  7.40  17.18
    ± SD   ± 176   ± 23   ± 5.37   ± 2.81   ± 13.9   ± 4.50   ± 4.02   ± 9.05
GOLD  II 20  mean  697  126  31.4 11.9 51.5 33.2  10.45  19.35
    ± SD   ± 227   ± 38   ± 3.31   ± 3.30   ± 12.1   ± 5.94   ± 4.39   ± 11.57
GOLD  III  19  mean  572  107  33.5 13.5 48.0 36.6  11.82  32.84
    ± SD   ± 247   ± 37   ± 6.1   ± 2.57   ± 6.97   ± 6.72   ± 4.35   ± 26.9
GOLD  IV  18  mean  558  117  37.4 17.5 39.9 40.9  15.43  40.46
    ± SD   ± 205   ± 39   ± 7.08   ± 3.23   ± 6.5   ± 6.76   ± 5.33   ± 44.5
ANOCOVA   F(χ2)group 1.76  1.54  3.299  45.79  64.45* 12.28  10.07  36.59*
   P group  0.128  0.185  0.009  <0.0001 <0.0001 <0.0001  <0.0001  <0.0001
   F cov  --  116.6 4.722 0.761 --  63.08  4.40  --
   P cov -- <0.0001  0.032  0.209  --  <0.0001  0.039  --
Abbreviations: VT , tidal volume; VD
aw, airways dead space; PETCO2, end-tidal CO2 partial pressure; IAH, index of alveolar heterogeneity; IVE, index of ventilatory efﬁ  ciency; 
VD
Bohr/VT , Bohr dead space ratio; Δ(VD
Bohr/VT), VD
Bohr/VT ratio real minus predicted; ΔSlIII , Slope of phase III real minus predicted.
Note: Fcorr and Pcorr are values corrected for VT effect in ANOVA analysis.
Table 3 Results of the multivariant analysis. Variables in the model are in bold
Parameter Height  BMI  Age  VT  FEV1%pred MEF%pred   
  T (Sig T)  T (Sig T)  T (Sig T)  T (Sig T)  T (Sig T)  T (Sig T)  R(multi)
 beta  beta  beta  beta beta  beta 
IVE  −1.40 (0.164)  1.85 (0.067)  −2.41 (0.018)  −0.70 (0.48)  2.78 (0.006) 2.82  (0.006)  0.825
  −0.084 0.110 −0.159  −0.042  0.379 0.379 
IHA 1.38  (0.170)  −1.07 (0.29)  1.40 (0.16)  −0.31 (0.76)  −14.4 (<0.0001)  −1.66 (0.099)  0.826
 0.079  −0.061 0.090  −0.017  −0.826  −0.218 
∆VD
Bohr/VT 0.050  (0.96)  −0.46 (0.64)  2.15 (0.034)  −1.74 (0.08)  −4.57 (0.0003) 0.80  (0.42)  0.560
 0.004  −0.041  0.205  −0.146  −0.436 0.158 
∆SlIII   1.87 (0.06)  0.87 (0.38)  0.084 (0.93)  −6.44 (<0.0001)  −6.33 (<0.0001) 0.63  (0.53)  0.683
 0.155  0.066  0.007  −0.483  −0.475 0.112 
VD
aw 1.54  (0.13)  −0.078 (0.94)  1.46 (0.15)  11.06 (<0.0001)  0.078 (0.94)  0.519 (0.13)  0.748
 0.115  −0.005 0.098  −0.130 0.005  0.035 
Abbreviations: VT ,Tidal volume; VD
aw, airways dead space; IAH, index of alveolar heterogeneity; IVE, index of ventilatory efﬁ  ciency; Δ(VD
Bohr/VT), VD
Bohr/VT ratio real minus 
predicted; ΔSlIII, slope of phase III real minus predicted.International Journal of COPD 2007:2(3) 388
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the probability of observing the same result in non-diseased 
individuals) was globally high in IAH, followed by IVE, and 
ΔSLIII but only at stage IV.
Discussion
According to our results, volumetric capnography parameters 
seem to be a good tool to determine the degree of functional 
involvement in COPD patients. It is generally considered that 
volumetric capnography reﬂ  ects the degree of pulmonary 
regional homogeneity in relation to gas exchange (Wolff and 
Brunner 1984; Fletcher and Jonson 1984; Hoffbrand 1966). 
From this point of view it seems reasonable to expect that 
volumetric capnography will reﬂ  ect the progression of alveo-
lar heterogeneity in parallel with that of the disease. Previous 
studies have shown some relationships between functional 
involvement in obstructive lung disease and speciﬁ  c indices 
obtained either from time based capnography (Toulou 1966; 
Smidt 1976; Worth 1986; You et al 1992) or from volumetric 
capnography in humans (Kars et al 1995; Kars et al 1997) and 
horses (Herholz et al 2002). However, no systematic analysis 
of the diagnostic capabilities of volumetric capnography in 
COPD patients has been carried on until now in humans. Recent 
technical and conceptual advances have allowed anticipation of 
better perspectives for clinical applications of capnography.
On the volumetric capnography 
parameters
We have used classical (VD
Bohr, SlIII) and newly developed 
parameters (VAE, PIE, VD
ser), as well as combinations of 
both (IAH, IVE). Historically, the clinical use of volumetric 
capnography has been limited for several reasons, one of 
them being the lack of a reliable measurement of VD
aw. The 
over-correction of phase II induces a phase III-dependent 
error in the classical, and most popular, equal area method. 
Nowadays, we can avoid this problem by taking into account 
the interface expired (Kars et al 1997; Åström et al 2000; 
Romero et al 1997). In fact, the ﬁ  nding that VD
aw, calculated 
according to Wolff and Brunner (1984), is unrelated to the 
disease stage in COPD supports this hypothesis.
Another factor that has limited the clinical use of volu-
metric capnography is the tidal dependence of the more 
usual capnography parameters. The use of predicted values 
means tidal dependence can be smoothed for VD
Bohr /VT, by 
subtracting the predicted value. A better result is obtained 
by using a common mode rejection ratio: IAH to completely 
eliminates the tidal dependence of VD
Bohr by referring it to 
VT–VD
aw (Equation 2). IVE, based on the alveolar ejection 
volume (VAE) measured on the VCO2(V) curve, also uses 
VT–VD
aw as reference eliminate the tidal dependence of 
VAE. Both IAH and IVE parameters are related to func-
tional troubles expressed during the alveolar phase of the 
capnogram. They are, therefore, physiologically related 
to regional distribution impairment as has been suggested 
by previous studies on normal subjects and COPD patients 
(Wilschut et al 1999; Hoffbrand 1966); however, the strong 
tidal dependence of SlIII could not be corrected even after 
subtraction of the predicted value calculated from tidal 
volume.
In 1997 Kars et al observed a good correlation between 
the degree of airways obstruction and the VD
Bohr normalised at 
1 L VT (R = –0.66). Our results are in concordance with this 
observation, as ΔVD
Bohr/VT has shown a signiﬁ  cant correlation 
with FEV1% pred. In the multivariate model we have used, 
however, age is signiﬁ  cantly correlated with ΔVD
Bohr/VT, a 
fact that was not noticed by Kars (1997) in COPD patients, 
or by Åström (2000) in normal subjects. In the study by Kars, 
only simple regressions were performed. Perhaps the age 
dependence we have observed is a surrogate dependence on 
Table 4 Receiver operating characteristics analysis (internal pevalence)
  Stage (cut-off)  AUC (95% C.I.)  Cut-off (95% C.I.)  PPV (range)  NPV (range)
    sens = spec    
IAH  Stage II   0.908 (0.884–0.982)  9.76 (9.43–10.1)  91.1 (89.5–92.6)  82.9 (82.1–83.3)
  Stage III  0.908 (0.833–0.957)  11.9 (11.1–12.7)  70.7 (69.6–75.8)  86.2 (81.5–92.3)
  Stage IV  0.926 (0.855–0.969)  14.2 (13.6–14.9)  53.6 (53.3–59.0)  95.8 (94.7–97.1)
IVE  Stage II   0.939 (0.873–0.977)  57.2 (55.6–58.7)  89.5 (88.2–92.3)  83.3 (80.0–85.6)
  Stage III  0.879 (0.798–0.936)  50.6 (49.9–51.3)  68.2 (67.7–69.4)  84.5 (67.6–69.1)
  Stage IV  0.902 (0.826–0.952)  45.5 (44.2–46.7)  51.7 (50.0–51.9)  95.7 (94.5–97.0)
∆VD
Bohr/VT  Stage II   0.788 (0.694–0.864)  9.6 (8.54–10.74)  76.0 (72.0–78.7)  59.8 (62.2–59.6)
  Stage III  0.777 (0.683–0.855)  11.0 (9.26–12.8)  52.3 (51.8–65.5)  74.5 (73.9–81.4)
  Stage IV  0.816 (0.725–0.886)  12.4 (10.7–14.1)  35.1 (34.0–42.0)  90.6 (88.3–96.2)
∆SlIII  Stage II   0.753 (0.656–0.834)  18.0 (16.9–19.1)  74.7 (72.7–74.9)  58.1 (56.0–59.1)
  Stage III  0.841 (0.753–0.906)  21.1 (20.5–21.7)  63.5 (62.9–66.7)  83.3 (84.1–83.0)
  Stage IV  0.871 (0.788–0.930)  28.4 (25.5–31.3)  85.2 (75.0–82.5)  80.6 (76.3–80.9)International Journal of COPD 2007:2(3) 389
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the clinical evolution of the disease. Unfortunately, there is 
no way to verify this hypothesis from our present data.
ROC curves analysis
In order to obtain an estimation of the diagnostic accuracy 
of each parameter, as well as to determine the cut-off 
for each stage level of the disease, we have performed a 
receiver operating characteristics (ROC) curve analysis. A 
reliable deﬁ  nition of the disease and a good estimation of its 
prevalence, are the key elements for using ROC curves with a 
high degree of statistical power. Clear guidelines for staging 
COPD patients have been published by the GOLD group. 
The staging process is based on spirometry, a completely 
standardised and reproducible technique, which leaves only 
a narrow margin for ambiguity. Prevalence data of COPD 
stages have been recently published by Kornmann et al 
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Figure 3 Receiver operating characteristics curve for each capnography parameter are plotted in separate boxes (∆VD
Bohr: Bohr dead space minus predicted value, ∆SlIII: 
Slope of alveolar phase or phase III minus predicted value, IAH: Index of Alveolar Heterogeneity, IVE: Index of   Ventilatory Efﬁ  ciency). In every box, each curve corresponds 
to a different stage of the disease.International Journal of COPD 2007:2(3) 390
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(2003). Because their results are somewhat different from the 
internal prevalence calculated in our population, they have 
been used to obtain the cumulated prevalence for Positive 
and Negative Predicted Values and Likelihood Ratio calcula-
tions, except for Stage 0 level which does not represent a true 
prevalence of COPD disease, but simply a cut-off point for a 
reference population of ex-smokers (cessation for more than 
10 years) with no clinical symptoms. Our population was not 
chosen to calculate the prevalence of COPD and that is why 
Stage Level 0 ROC Predicted Values and Likelihood Ratio 
do not correspond to the social prevalence of the disease. 
Furthermore, the stage-related variation of PPV and NPV 
may be inﬂ  uenced by their prevalence-dependence because 
we have used the cumulative prevalence in the ROC curve 
analysis. In contrast, sensitivity and speciﬁ  city values, AUC 
and cut-off points, which are prevalence-independent are 
therefore valid for all stages, including stage 0.
The area under the ROC curve (AUC) is a global summary 
statistic of diagnostic accuracy. According to an arbitrary 
guideline (based on a suggestion by Swets in 1988), it is 
possible to distinguish between non-informative (AUC = 0.5), 
less accurate (0.5 0.7 0.9), highly accurate (0.9 AUC 
1) and perfect tests (AUC = 1). It has been recognised that 
AUC is equivalent to the probability that a randomly drawn 
individual from the positive reference sample has a higher (or 
lower) test value than a randomly drawn individual from the 
negative reference sample. As AUC gives equal weighting 
to sensitivity and speciﬁ  city, we have considered the point at 
which speciﬁ  city equals sensitivity as the cut-off point for all 
stages. However, other criteria could be used if we consider, 
for instance, the misclassiﬁ  cation cost (False Positive and 
False Negative Cost, CFP and CFN respectively), which 
require quantiﬁ  cation of the consequences of misclassiﬁ  cation 
(Greiner et al 2000). Without better information we have a 
priori considered that CFP = CFN, and we have given equal 
weight to sensitivity and speciﬁ  city.
In a previous study Herholtz et al (2002) studied the 
diagnostic value of volumetric capnography parameters 
in a population of horses suffering from recurrent airways 
obstruction (a veterinary equivalent of COPD in horses). 
In their study the best accuracy was obtained for VD
Bohr/VT 
(AUC = 0.70, Se = Sp = 63%) in the staging between with-
out symptoms and with symptoms horses, equivalent to our 
stage 0 for which we have obtained nearly identical results 
using ΔVD
Bohr/VT (AUC = 0.68, Se = Sp = 63%). However 
practically all our AUC have been over 0.7.
In conclusion, capnography parameters seem to be use-
ful for staging COPD patients when spirometry is difﬁ  cult 
to perform because of technical or clinical constraints. 
Capnography is an easy-to-perform technique that requires 
no special effort or particular knowledge of the manoeuvre, 
and can be performed in severely disabled patients. It can be 
used as an alternative test to diagnose the severity of func-
tional impairment in these patients. The Index of Alveolar 
Heterogeneity seems to be the best parameter for use in 
clinical practice.
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Abbreviations
ANOVA, Analysis of variance; AUC, Area Under the 
(ROC) Curve; BMI, Body Mass Index; CFN, False Nega-
tive Cost; CFP, False Positive Cost; COD, Coefﬁ  cient of 
Determination; ΔSlIII, Slope of phase III real minus predicted; 
ΔVD
Bohr/VT, VD
Bohr/VT ratio real minus predicted; Fcov, Fisher 
F for covariance analysis; PETCO2, End tidal CO2 partial 
pressure; FEV1%pred, Forced Expiratory Volume in one 
second in percent of predicted; Fgroup, Fisher For inter-group 
comparison; IAH, Index of Alveolar Heterogeneity; IVE, 
Index of Ventilatory Efﬁ  ciency; MMEF%pred, Maximal 
Mid Expiratory Flow in percent of predicted; NPV, Negative 
Predicted Value; Pcov, Probability associated to Fcov; Pgroup, 
Probability associated to Fgroup or χ2
group; PIE, Pre-interface 
expirate; PLR, Positive Likelihood ratio; PPV, Positive 
Predicted Value; ROC, Receiver Operating Characteristics 
Curve; Se, Sensitivity; SlIII, Slope of Phase III or alveolar 
phase in the capnogram; Sp, Speciﬁ  city; VAE, Volume of 
alveolar ejection; VCO2(V), Curve of VCO2 versus exhaled 
volume; VD
aw, Airways Dead Space; VD
ser, Serial Dead Space 
(includes instrumental dead space); VECO2, CO2 rejected by 
breath; VT, Tidal Volume; χ2
group
 , Chi squared from Kruskal-
Wallis rank test;
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